Clinical feature | ALK+S-ALCL | P | ALK-S-ALCL | P | ||
---|---|---|---|---|---|---|
 | This report | Savage et al. |  | This report | Savage et al. |  |
Total no.patients (≥19 years) | 23 | 87 |  | 31 | 72 |  |
Median age, y | 38 | 34 | Â | 34 | 58 | Â |
Age less than 60 y, no. (%) | 22(96) | 74(86) | 0.175 | 26(84) | 42(58) | <0.05 |
Male–female ratio | 2.8:1 | 1.7:1 | 0.34 | 1.8:1 | 1.5:1 | 0.68 |
Stage, no.(%) | Â | Â | 0.07 | Â | Â | 0.53 |
I | 9(40) | 1(0) | Â | 8(26) | 0(0) | Â |
II | 4(17) | 30(35) | Â | 7(23) | 30(42) | Â |
III | 6(26) | 25(29) | Â | 10(32) | 15(21) | Â |
IV | 4(17) | 31(36) | Â | 6(20) | 27(37) | Â |
Nodal-only disease, no. (%) | 11(48) | 39(54) | 0.8 | 13(42) | 38(49) | 0.31 |
Extranodal sites more than 1, no. (%) | 4(17) | 17(19.5) | 0.82 | 5(16) | 15(21) | 0.58 |
Extranodal sites, no. (%) | Â | Â | Â | Â | Â | Â |
Bone marrrow | 0 | 10(12) | 0.09 | 2(5) | 5(7) | 0.93 |
Subcutaneous tissue | 0(0) | 9(10) | 0.1 | 1(3) | 2(3) | 0.9 |
Lung | 2(8) | 7(8) | 0.92 | 1(3) | 9(13) | 0.14 |
Bone | 3(6) | 12(14) | 0.93 | 2(5) | 5(7) | 0.93 |
Skin | 5(10) | 7(8) | 0.06 | 5(16) | 12(17) | 0.95 |
Liver | 1(4) | 3(3) | 0.84 | 2(6) | 7(10) | 0.59 |
Spleen | 1(4) | 9(10) | 0.37 | 4(13) | 2(3) | <0.05 |
Pleural effusion | 1(4) | 3(3) | 0.84 | 2(6) | 4(6) | 0.86 |
Pericardial effusiom | 0(0) | 0(0) | 0.6 | 1(3) | 1(1) | 0.54 |
B symptoms, no. (%) | 9(39) | 52(60) | 0.08 | 11(35) | 41(57) | <0.05 |
5-y OS, % | 58 | 70 | Â | 35 | 49 | Â |